Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study

Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study

Background Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib ph...

Full description

Bibliographic Details
Main Authors: Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Journal of Dermatological Treatment
Subjects:
atopic dermatitis
janus kinase inhibitor
ruxolitinib nanoliposome
Online Access:http://dx.doi.org/10.1080/09546634.2022.2112138

Internet

http://dx.doi.org/10.1080/09546634.2022.2112138

Similar Items